Novo Nordisk boosts full-year profit and sales outlook on weight-loss drug demand

 Novo Nordisk (NOVO-B.KO) said it's increased its forecast for full-year sales and operating profit at constant exchange rates. The Danish insulin maker said in the first quarter, at constant exchange rates, its operating profit rose 28% on sales growth of 25%. Thanks mostly to prescription trends for weight-loss drug Wegovvy, Novo Nordisk now expects operating profit growth between 28% and 34% on sales growth between 24% and 30%, vs. its earlier view of 13% to 19% growth in both operating profit and sales for the year. Earlier, Credit Suisse had upgraded the stock, citing Ozempic growth acceleration and Wegovy re-launch.

https://www.morningstar.com/news/marketwatch/20230413312/novo-nordisk-boosts-full-year-profit-and-sales-outlook-on-weight-loss-drug-demand